Holen Sie sich die Stockscreener-App
1.42
5.96%
-0.09
Handel nachbörslich:
1.37
-0.05
-3.52%
Pepgen Inc Aktie (PEPG) Neueste Nachrichten
Petri Dish: PepGen halts work on Duchenne drug; Needham biotech announces layoffs - The Business Journals
Pepgen pulls plug on exon-skipping therapy for Duchenne MD - Muscular Dystrophy News
PepGen Inc. (NASDAQ:PEPG) Shares Bought by Deutsche Bank AG - Defense World
Leerink Partnrs Forecasts PepGen’s Q3 Earnings (NASDAQ:PEPG) - Defense World
Northern Trust Corp Purchases 7,984 Shares of PepGen Inc. (NASDAQ:PEPG) - Defense World
H.C. Wainwright cuts PepGen stock price target to $8, keeps Buy rating - Investing.com Nigeria
H.C. Wainwright cuts PepGen stock price target to $8, keeps Buy rating By Investing.com - Investing.com South Africa
PepGen price target lowered to $1 from $3 at BofA - Yahoo Finance
PepGen to discontinue DMD programs after PGN-EDO51 did not achieve target - Yahoo Finance
PepGen Inc.’s Strategic Shift to DM1 Program Earns Buy Rating Amid Promising Developments - TipRanks
PepGen (NASDAQ:PEPG) Price Target Lowered to $8.00 at HC Wainwright - Defense World
PepGen Inc. (PEPG) Halts DMD Program After Trial Miss; Shifts Focus to DM1 - MSN
PepGen (PEPG) Adjusts Focus After Discontinuing DMD Program | PE - GuruFocus
PepGen (PEPG) Shifts Focus from DMD as PGN-EDO51 Results Disappo - GuruFocus
PepGen (PEPG) Price Target Lowered by Analyst HC Wainwright & Co. | PEPG Stock News - GuruFocus
PepGen (PEPG) Faces Price Target Cut as Key Program Ends | PEPG Stock News - GuruFocus
PepGen Inc. Receives Buy Rating from Ananda Ghosh Due to Strategic Focus on Promising DM1 Program - TipRanks
PepGen Inc.’s Strategic Shift Amidst DMD Program Discontinuation and Competitive Challenges - TipRanks
PepGen price target lowered to $8 from $14 at H.C. Wainwright - TipRanks
PepGen (PEPG) Shifts Focus from DMD as PGN-EDO51 Results Disappoint | PEPG Stock News - GuruFocus
PepGen (PEPG) Adjusts Focus After Discontinuing DMD Program | PEPG Stock News - GuruFocus
PepGen Abandons Duchenne Program, Shifts Spotlight To Another Rare Disease Candidate - Benzinga
PepGen to discontinue development of experimental Duchenne therapy; shares drop - whbl.com
PepGen Inc. Discontinues DMD Programs After Trial Results - TipRanks
PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update - Business Wire
PepGen appoints new CTO to advance therapies By Investing.com - Investing.com South Africa
PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer - citybiz
PepGen Appoints New CTO with Bluebird Bio Experience | BLUE Stoc - GuruFocus
PepGen Appoints New CTO with Bluebird Bio Experience | BLUE Stock News - GuruFocus
PepGen appoints new CTO to advance therapies - Investing.com
PepGen Inc. (NASDAQ:PEPG) Holdings Lifted by Dimensional Fund Advisors LP - Defense World
PepGen Inc.’s Promising Advances in DMD and DM1 Programs Justify Buy Rating - TipRanks
PepGen Inc reports results for the quarter ended March 31Earnings Summary - TradingView
HC Wainwright Cuts PepGen (NASDAQ:PEPG) Price Target to $14.00 - Defense World
PepGen Inc. Reports Q1 2025 Financial Results - TipRanks
ATTENTION PEPG SHAREHOLDERS: Investors Who Lost Money on PepGen Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation - ACCESS Newswire
PepGen stock price target cut to $14 from $16 by H.C. Wainwright - Investing.com Nigeria
PepGen (PEPG) Stock Target Price Lowered by HC Wainwright & Co. - GuruFocus
PepGen (PEPG) Price Target Adjusted by H.C. Wainwright Analyst | PEPG Stock News - GuruFocus
PepGen (PEPG) Price Target Adjusted by H.C. Wainwright Analyst | - GuruFocus
PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - BioSpace
PepGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
0.86%
1.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):